Don’t Look Up? Investors Call For Tweaks To Small Molecule Provisions In US Pricing Bill
Budget Neutral Fix Could Mean Continued Innovation
Executive Summary
Investors and pharma stakeholders scramble to extend the time period before small molecule drugs are subject to government mandated discounts as Senate drug pricing legislation moves toward a floor vote.